Division of Reparative Medicine, Department of Gastrointestinal and Pediatric Surgery, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan.
Oncology. 2013;84(2):100-7. doi: 10.1159/000343822. Epub 2012 Nov 9.
The inflammation-based Glasgow Prognostic Score (GPS) is associated with outcome in a variety of cancers. This study investigated whether a modified GPS (mGPS) could predict survival in patients undergoing multimodality therapy for advanced colorectal cancer (CRC).
We enrolled 245 patients with advanced CRC who received chemotherapy. The mGPS was recorded prior to first-line chemotherapy and to cytoreductive therapy including secondary surgery and/or radiofrequency ablation. The prognostic significance of the mGPS was analyzed using Kaplan-Meier, univariate, and multivariate analyses.
In patients who received chemotherapy alone (n = 163), the mGPS prior to chemotherapy was an independent prognostic indicator of survival [odds ratio (OR) 1.858; 95% confidence interval (CI) 1.213-2.846; p = 0.0044]. In patients who also underwent cytoreductive therapy (n = 82), the mGPS decreased after chemotherapy in 22 patients (27%) and increased in 5 (6%). In these patients, the mGPS prior to cytoreductive therapy was an independent prognostic indicator of survival (OR 3.412; 95% CI 1.198-9.720; p = 0.0216), but the mGPS prior to chemotherapy was not.
The mGPS is an independent prognostic indicator of survival in patients undergoing multimodality therapy for advanced CRC, if recorded at a relevant time point.
基于炎症的格拉斯哥预后评分（GPS）与多种癌症的预后相关。本研究旨在探讨改良 GPS（mGPS）能否预测接受多模式治疗的晚期结直肠癌（CRC）患者的生存情况。
我们纳入了 245 例接受化疗的晚期 CRC 患者。在一线化疗前以及包括二次手术和/或射频消融的细胞减灭治疗前记录 mGPS。采用 Kaplan-Meier、单因素和多因素分析来分析 mGPS 的预后意义。
在仅接受化疗的患者（n=163）中，化疗前的 mGPS 是生存的独立预后指标[比值比（OR）1.858；95%置信区间（CI）1.213-2.846；p=0.0044]。在还接受细胞减灭治疗的患者（n=82）中，22 例（27%）患者在化疗后 mGPS 下降，5 例（6%）患者 mGPS 升高。在这些患者中，细胞减灭治疗前的 mGPS 是生存的独立预后指标（OR 3.412；95%CI 1.198-9.720；p=0.0216），但化疗前的 mGPS 不是。
如果在相关时间点记录，mGPS 是接受多模式治疗的晚期 CRC 患者生存的独立预后指标。
